Richard Goldstein, MD
March 2, 2021
Jagruti Oza
March 2, 2021

In The News

Bruce Johnson

Bruce Johnson is the Executive Vice President and Chief Commercial Officer of CEN.  He has more than 25 years of oncology therapeutic area and life sciences industry experience working with pharmaceutical and academic institutions. He has deep expertise in the areas of strategy development and strategic brand planning, product launch, marketing, business development, new product evaluation and post-merger integration. Bruce is a published author and has been directly involved in the successful launch of several leading oncology and hematology brands, including: Gleevec®/Glivec®, Tasigna®, Aredia®, Zometa®, Exjade®, Promacta®/ Revolade®, Afinitor®, Jakavi®, Zykadia®, Sandostatin®, Sandostatin LAR® Depot, Rydapt®, Venclexta® and Imbruvica®. 

Prior to joining Pharma Health Labs and Cancer Expert Now, Bruce was Vice President, Oncology Global Commercial Development at AbbVie. Bruce was also Vice President and Global Franchise Head, Malignant Hematology at Novartis Pharmaceuticals Corporation and received his oncology training at MSKCC as a Clinical Research and Data Coordinator for the GI Solid Tumor Service. 

Industry Specialization: Healthcare and Life Sciences, Pharmaceuticals, Diagnostics